Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race to TIG­IT dom­i­na­tion?

Roche caused quite a stir at AS­CO with its first look at some pos­i­tive — but not so im­pres­sive — da­ta for their com­bi­na­tion of Tecen­triq with their an­ti-TIG­IT drug tiragolum­ab. But some an­a­lysts be­lieve that Mer­ck is po­si­tioned to make a bid — soon — for the lead in the race to a sec­ond-wave com­bo im­muno-on­col­o­gy ap­proach with its own am­bi­tious ear­ly-stage pro­gram tied to a dom­i­nant Keytru­da.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.